Remikiren: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 24: | Line 24: | ||
|routes_of_administration= | |routes_of_administration= | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Remikiren''' is a [[renin inhibitor]] under development for the treatment of [[hypertension]] (high blood pressure). It was first developed by [[Hoffmann–La Roche]] in 1996.<ref>{{cite journal |author=Richter WF, Whitby BR, Chou RC |title=Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals |journal=Xenobiotica |volume=26 |issue=3 |pages=243–54 |year=1996 |pmid=8730917 |doi=}}</ref> | '''Remikiren''' is a [[renin inhibitor]] under development for the treatment of [[hypertension]] (high blood pressure). It was first developed by [[Hoffmann–La Roche]] in 1996.<ref>{{cite journal |author=Richter WF, Whitby BR, Chou RC |title=Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals |journal=Xenobiotica |volume=26 |issue=3 |pages=243–54 |year=1996 |pmid=8730917 |doi=10.3109/00498259609046705}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | |||
{{Agents acting on the renin-angiotensin system}} | {{Agents acting on the renin-angiotensin system}} | ||
[[Category:Renin inhibitors]] | [[Category:Renin inhibitors]] | ||
[[Category:Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drug]] | |||
[[ | |||
Latest revision as of 21:14, 23 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 83% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C33H50N4O6S |
| Molar mass | 630.839 g/mol |
|
WikiDoc Resources for Remikiren |
|
Articles |
|---|
|
Most recent articles on Remikiren |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Remikiren at Clinical Trials.gov Clinical Trials on Remikiren at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Remikiren
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Remikiren Discussion groups on Remikiren Directions to Hospitals Treating Remikiren Risk calculators and risk factors for Remikiren
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Remikiren |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.[1]
References
- ↑ Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica. 26 (3): 243–54. doi:10.3109/00498259609046705. PMID 8730917.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Renin inhibitors
- Cardiovascular Drugs
- Drug